💾 Data Updated: 2025 HTS Revision 30 • Last updated: November 24, 2025

3002 - Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products; cell cultures, whether or not modified:

Sub-classifications

Commodity Code
Description

Overview

Heading 3002 encompasses a broad range of biological products derived from humans and animals, primarily intended for therapeutic, prophylactic, or diagnostic purposes. This category includes vital substances like human and animal blood, carefully prepared for medicinal applications. It also covers antisera, which are antibodies used to treat or prevent disease, along with other blood fractions and immunological products. The scope extends to advanced biotechnologically produced substances, highlighting the inclusive nature of this heading towards modern biological advancements.

Unlike sibling categories within Chapter 30, which might focus on pharmaceuticals derived from plants (e.g., heading 3001 for glands and other organs) or prepared drugs and medicines (e.g., heading 3004), heading 3002 specifically targets products of biological origin related to the immune system and microbial cultures. It is distinct from categories outside of Chapter 30, such as live animals in Chapter 01, or chemical compounds in Chapter 29, by virtue of its reliance on biological sources and inherent biological activity.

The subcategories within 3002 further refine the classification of these complex biological products. "Antisera, other blood fractions and immunological products" captures a significant portion of the heading's scope, focusing on passive immunity and therapeutic blood components. "Vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products" addresses active immunization and diagnostic agents derived from microorganisms. Finally, "Cell cultures, whether or not modified" acknowledges the growing field of cellular therapies and research. The residual category "Other" exists to capture any products that fall under the broad description of 3002 but are not specifically enumerated in the preceding subheadings.

Stay Updated

Join our newsletter to get all updates of the harmonized Tariff Schedule.